Currently, cabergoline, a dopamine agonist (DA), is generally the first-line treatment of choice for prolactinomas [5], which reduces the size of tumor and normalizes PRL, leading to alleviation of endocrine and neurologic symptoms in 80–95% of patients during the first month of treatment [6,7]. Here, PRL is linked to neoplasm.